BioCentury
ARTICLE | Clinical News

Avastin bevacizumab: Phase III data

September 27, 2010 7:00 AM UTC

Top-line data from the Phase III AVANT trial in 3,451 patients who had undergone surgery for high-risk stage II and III colon cancer showed that Avastin plus FOLFOX or XELOX chemotherapy missed the primary endpoint of significantly improving disease-free survival vs. FOLFOX chemotherapy alone. Additionally, more patients receiving Avastin plus chemotherapy relapsed at 3 years of follow up vs. chemotherapy alone. Roche said it is evaluating data from the Phase III AVANT and NSABP C-08 trials to determine the next steps for Avastin as an adjuvant therapy for early stage colon cancer. Patients received 5 mg/kg Avastin every 2 weeks plus FOLFOX for 24 weeks, followed by 7.5 mg/kg Avastin alone every 3 weeks for an additional 24 weeks; 7.5 mg/kg Avastin every 3 weeks plus XELOX for 24 weeks, followed by 7.5 mg/kg Avastin alone every 3 weeks for an additional 24 weeks; or FOLFOX alone for 24 weeks, followed by observation alone for 24 weeks. ...